Inclusion Criteria:

   - Patients with histologically documented epithelial carcinoma arising in the ovary,
   fallopian tube, or peritoneum, of any stage or grade at diagnosis; all patients must
   have had cytoreductive surgery and chemotherapy with at least one platinum-based
   chemotherapy regimen as part of primary treatment

   - Patients who recurred on or after initial therapy, and are now in a second or third
   complete clinical remission and who are within four months of their last treatment are
   eligible; complete clinical remission is defined as serum cancer antigen (CA)-125
   within institutional normal limits, negative physical examination, and no definite
   evidence of disease by computed tomography (CT) of the abdomen and pelvis; lymph nodes
   and/or soft tissue abnormalities =< 1.0 cm are often present in the pelvis and will
   not be considered definite evidence of disease; eligibility is determined by
   anatomical imaging only (ie. magnetic resonance imaging [MRI] or CT); a positive
   positron emission tomography (PET) image (if performed) will not exclude a patient if
   other criteria are met and anatomical imaging is negative

   - Absolute neutrophil count (ANC) greater than or equal to 1,000/mm^3, equivalent to
   Common Toxicity Criteria for Adverse Events (CTCAE version [v]4.0) grade 1

   - Platelets greater than or equal to 100,000/mm^3

   - Serum creatinine less than or equal to 1.5 x institutional upper limit normal (ULN),
   CTCAE v4.0 grade 1

   - Bilirubin less than or equal to 2.5 x ULN

   - Serum glutamic oxaloacetic transaminase (SGOT), serum glutamate pyruvate transaminse
   (SGPT) less than or equal to 2.5 x ULN

   - Alkaline phosphatase less than or equal to 2.5 x ULN

   - Patients must have a Gynecological Oncology Group (GOG) performance status of 0, 1, or
   2

   - Patients who have signed the informed consent document and signed the authorization
   permitting release of personal health information

   - Patients of childbearing potential must have a negative serum pregnancy test prior to
   study entry and must be practicing an effective form of birth control; nursing mothers
   are excluded

Exclusion Criteria:

   - With the exception of non-melanoma skin cancer, patients with other invasive
   malignancies who had (or have) any evidence of the other cancer present within the
   last 5 years or whose previous cancer treatment contraindicates this protocol therapy
   are excluded

   - Patients whose circumstances at the time of entry onto the protocol would not permit
   completion of study or required follow up

   - Patients who have an allergy to shellfish